Every Form 4 that Fractyl Health (GUTS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GUTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GUTS filings page.
FRACTYL HEALTH, INC. director Ajay Royan made an open-market purchase of 23,000 shares of common stock on June 12, 2026 at a price of $0.852 per share. Following this trade, he directly holds 40,901 common shares.
Separately, the filing reports indirect holdings attributed to investment entities: 1,251,900 shares held by Mithril LP and 5,160,301 shares held by Mithril II LP. Royan may be deemed to have beneficial ownership through these entities but disclaims beneficial ownership except to the extent of any pecuniary interest.
FRACTYL HEALTH, INC. director William Bradley reported an open-market purchase of 68,493 shares of Common Stock at about $0.7348 per share, bringing his direct holdings to 84,622 shares. He also received a grant of stock options for 22,500 shares at a $0.7318 exercise price, expiring in 2036-06-09, which vest at the next annual stockholder meeting or the first anniversary of grant, subject to continued board service.
FRACTYL HEALTH, INC. director Samuel Conaway received a grant of stock options covering 22,500 shares of common stock at an exercise price of $0.7318 per share. These options were awarded as compensation for his board service and will vest in a single installment on the earlier of the next annual stockholder meeting or the first anniversary of the grant, subject to continued board service. Following this award, he holds 22,500 stock options directly.
FRACTYL HEALTH, INC. director Ajay Royan received a grant of stock options covering 22,500 shares of common stock at an exercise price of $0.7318 per share as compensation for service on the board.
The options vest in a single installment on the earlier of the next annual stockholder meeting or the first anniversary of the grant, subject to his continued service as a non-employee director, and expire on June 9, 2036. Following this award, Royan holds 22,500 stock options directly.
FRACTYL HEALTH, INC. director Christopher Charles Thompson received a grant of stock options covering 22,500 shares of common stock as compensation for his service on the board under the non-employee director compensation policy. The options have an exercise price of $0.7318 per share and expire on June 9, 2036. They vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, subject to his continued service as a non-employee director. Following this award, he holds 22,500 stock options directly.
FRACTYL HEALTH, INC. director Marc Elia received a stock option grant covering 22,500 shares of common stock as compensation for board service. The option has an exercise price of $0.7318 per share and expires on June 9, 2036.
The award will vest and become exercisable in a single installment on the earlier of the next annual stockholder meeting or the first anniversary of the grant, subject to Elia’s continued service as a non-employee director. After this grant, he holds 22,500 stock options directly.
FRACTYL HEALTH, INC. director Kelly Ann Barnes received a grant of stock options covering 22,500 shares of common stock as compensation for her board service. The options have an exercise price of $0.7318 per share and expire on June 9, 2036.
According to the terms, the award will vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, in each case subject to her continued service as a non-employee director. Following this grant, she holds 22,500 options directly.
FRACTYL HEALTH, INC. director Clive Meanwell received a grant of stock options as part of his non-employee director compensation. The award covers 22,500 options for common stock at an exercise price of $0.7318 per share, expiring on June 9, 2036.
The options vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, assuming continued service on the board. Following this grant, Meanwell holds 22,500 stock options directly, with no open-market purchases or sales reported.
FRACTYL HEALTH, INC. director Ian Sheffield reported an open-market purchase and an option grant. He bought 35,000 shares of Common Stock at $0.7294 per share, giving him 35,000 shares held directly after the transaction.
He was also granted 22,500 stock options with an exercise price of $0.7318 per share, each for one share of Common Stock and expiring on June 9, 2036. The option vests in a single installment on the earlier of the next annual stockholder meeting or the first anniversary of the grant, subject to his continued service on the board as a non-employee director.
Fractyl Health, Inc. Chief Executive Officer Harith Rajagopalan reported an open-market purchase of 25,000 shares of common stock on June 10, 2026 at a weighted average price of $0.7301 per share, with trade prices ranging from $0.7213 to $0.7324.
Following this transaction, he directly holds 540,557 shares of common stock and indirectly holds additional shares through three trusts with reported positions of 18,639, 292,170, and 292,171 shares. His holdings also include 13,812 shares purchased under the company’s 2024 Employee Stock Purchase Plan on January 30, 2026 at $0.391 per share.
FRACTYL HEALTH, INC. Chief Financial Officer Lara Smith Weber reported an open-market purchase of 20,000 shares of common stock. The shares were bought on June 8, 2026 at a weighted average price of $0.6854 per share, in multiple trades between $0.6844 and $0.6896. Following this transaction, she directly owns 20,000 common shares.
Fractyl Health reported a new stock option grant to its Chief Financial Officer, Lara Smith Weber. On January 12, 2026, she was awarded a stock option covering 1,036,800 shares of common stock with an exercise price of $2 per share.
The option vests over time: 25% of the shares become exercisable on January 12, 2027, and the remaining 75% vest in 36 equal monthly installments after that date, contingent on her continued service with the company. Following this grant, she directly beneficially owns 1,036,800 derivative securities in the form of stock options.
Fractyl Health, Inc. reported a new stock option grant for its General Counsel on a Form 4. On 12/15/2025, the officer received a stock option to purchase 743,913 shares of common stock at an exercise price of $2.24 per share. The option is listed as being held with direct ownership of 743,913 derivative securities following the transaction.
According to the disclosure, the stock option vests in equal installments on each of the first three anniversaries of the grant date, so the award becomes exercisable over a three-year period as long as the General Counsel remains employed through each vesting date. The option has an expiration date of 12/14/2035, giving a long-term window in which the award can be exercised once vested.
Fractyl Health, Inc. reported that one of its officers, serving as President and Chief Product Officer, received a stock option grant on 12/15/2025. The option covers 845,226 shares of common stock at an exercise price of $2.24 per share and expires on 12/14/2035.
According to the disclosure, the option vests and becomes exercisable in equal installments on each of the first three anniversaries of the grant date, as long as the officer remains employed through each vesting date. Following this grant, the officer beneficially owns 845,226 derivative securities, held directly.
Fractyl Health, Inc. disclosed an insider equity award for its Chief Executive Officer and director, Harith Rajagopalan. A stock option covering 2,486,302 shares of common stock was granted on 12/15/2025 at an exercise price of $2.24 per share, with an expiration date of 12/14/2035.
The option vests and becomes exercisable in equal installments on each of the first three anniversaries of the grant date, as long as the reporting person remains employed through each vesting date. Following this grant, the filing reports beneficial ownership of 2,486,302 derivative securities held directly.